Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
Classement en actions
#4334
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
Prix de l'action
$3.87
Capitalisation boursière
$3.57B
Changement (1 jour)
-1.64%
Changement (1 an)
9.08%
Pays
CN
Échange Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Catégorie
Healthcare
Ratio P/B pour Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
Ratio P/B au October 2026 TTM : 1.74
Selon les derniers rapports financiers et le cours de l'action de Hubei Jumpcan Pharmaceutical Co., Ltd., le ratio cours/valeur comptable actuel (TTM) est 1.74. À la fin de 2024, le ratio P/B était de 1.81.
Historique du ratio P/B pour Hubei Jumpcan Pharmaceutical Co., Ltd. de 2001 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| 2026 (TTM) | 1.74 | 4.72% |
| 2025 | 1.66 | -8.58% |
| 2024 | 1.81 | -20.64% |
| 2023 | 2.29 | 7.03% |
| 2022 | 2.14 | -22.64% |
| 2021 | 2.76 | 26.93% |
| 2020 | 2.18 | -32.61% |
| 2019 | 3.23 | -28.06% |
| 2018 | 4.49 | -36.34% |
| 2017 | 7.05 | 3.38% |
| 2016 | 6.82 | -15.47% |
| 2015 | 8.07 | 21.15% |
| 2014 | 6.66 | -37.14% |
| 2013 | 10.59 | 28.54% |
| 2012 | 8.24 | 390.60% |
| 2011 | 1.68 | -34.12% |
| 2010 | 2.55 | 54.33% |
| 2009 | 1.65 | 76.47% |
| 2008 | 0.94 | -55.17% |
| 2007 | 2.09 | 104.82% |
| 2006 | 1.02 | 4.08% |
| 2005 | 0.98 | -17.76% |
| 2004 | 1.19 | -24.51% |
| 2003 | 1.58 | -39.47% |
| 2002 | 2.61 | -31.82% |
| 2001 | 3.82 | 0.00% |
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 1.3124 | -24.51% |
JP
|
|
| 6.3468 | 265.09% |
CH
|
|
| 5.041 | 189.98% |
IN
|
